The CCR5 and CXCR4 Coreceptors - Central to Understanding the Transmission and Pathogenesis of Human Immunodeficiency Virus Type 1 Infection

AIDS Research and Human Retroviruses

Volumn 20, Issue 1, 2004, Pages 111-126

  Moore, John P ^a   Kitchen, Scott G ^b   Pugach, Pavel ^a   Zack, Jerome A ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5;

CELL TYPE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE SYSTEM; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; THYMUS; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; HIV INFECTIONS; HIV-1; HUMANS; INFANT; PHENOTYPE; RECEPTORS, CCR5; RECEPTORS, CXCR4;

EID: 0742325043     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922204322749567     Document Type: Short Survey

References (233)

1. Cocchi F, De Vico AL, Garzino-Demo A, Arya SK, Gallo RC, and Lusso P: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-1815.
2. Feng Y, Broder CC, Kennedy PE, and Berger EA: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-877.
3. Alkhatib G, Combadiere C, Broder CC, et al.: CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272:1955-1958.
4. Choe H, Farzan M, Sun Y, et al.: The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135-1148.
5. Deng H, Liu R, Ellmeier W, et al.: Identification of a major coreceptor for primary isolates of HIV-1. Nature 1996;381:661-666.
6. Doranz BJ, Rucker J, Yi Y, et al.: A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996;85: 1149-1158.
7. Dragic T, Litwin V, Allaway GP, et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-673.
8. Liu R, Paxton WA, Choe S, et al.: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-377.
9. Dean M, Carrington M, Winkler C, et al.: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996;273:1856-1862.
10. Paxton WA, Martin SR, Tse D, et al.: Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med 1996;2:412-417.
11. Samson M, Libert F, Doranz BJ, et al.: Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine reeptor gene. Nature 1996;382:722-725.
12. Douek DC, Picker LJ, and Koup RA: T cell dynamics in HIV-1 infection. Annu Rev Immunol 2003;21:265-304.
13. Doms RW: Chemokine receptors and HIV entry. AIDS 2001;15(Suppl. 1):S34-35.
14. Berger EA, Murphy PM, and Farber JM: Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu Rev Immunol 1999;17:657-700.
15. Lee S, Tiffany HL, King L, Murphy PM, Golding H, and Zaitseva MB: CCR8 on human thymocytes functions as a human immunodeficiency virus type 1 coreceptor. J Virol 2000;74:6946-6952.
16. Sharron M, Pohlmann S, Price K, et al.: Expression and coreceptor activity of STRL33/Bonzo on primary peripheral blood lymphocytes. Blood 2000;96:41-49.
17. Zhang YJ, Zhang L, Ketas T, Korber BT, and Moore JP: HIV type 1 molecular clones able to use the Bonzo/STRL-33 coreceptor for virus entry. AIDS Res Hum Retroviruses 2001;17: 217-227.
18. Zhang YJ, Dragic T, Cao Y, et al.: Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. J Virol 1998;72:9337-9344.
19. Willey SJ, Reeves JD, Hudson R, et al.: Identification of a subset of human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus strains able to exploit an alternative coreceptor on untransformed human brain and lymphoid cells. J Virol 2003;77:6138-6152.
20. Connor RI, Sheridan KE, Ceradini D, Choe S, and Landau NR: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185:621-628.
21. de Roda Husman AM, van Rij RP, Blaak H, Broersen S, and Schuitemaker H: Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression. J Infect Dis 1999;180:1106-1115.
22. Edinger AL, Hoffman TL, Sharron M, Lee B, O'Dowd B, and Doms RW: Use of GPR1, GPR15, and STRL33 as coreceptors by diverse human immunodeficiency virus type 1 and simian immunodeficiency virus envelope proteins. Virology 1998;249: 367-378.
23. Kreisberg JF, Kwa D, Schramm B, et al.: Cytopathicity of human immunodeficiency virus type 1 primary isolates depends on coreceptor usage and not patient disease status. J Virol 2001;75: 8842-8847.
24. Pohlmann S, Lee B, Meister S, et al.: Simian immunodeficiency virus utilizes human and sooty mangabey but not rhesus macaque STRL33 for efficient entry. J Virol 2000;74:5075-5082.
25. Simmons G, Wilkinson D, Reeves JD, et al.: Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J Virol 1996;70:8355-8360.
26. Zhang YJ and Moore JP: Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry? J Virol 1999;73:3443-3448.
27. Sheppard HW, Celum C, Michael NL, et al.: HIV-1 infection in individuals with the CCR5-delta32/delta32 genotype: Acquisition of syncytium-inducing virus at seroconversion. J Acquir Immune Defic Syndr 2002;29:307-313.
28. Michael NL, Nelson JA, KewalRamani VN, et al.: Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. J Virol 1998;72:6040-6047.
29. Gorry PR, Zhang C, Wu S, et al.: Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5 delta32 allele. Lancet 2002;359:1832-1834.
30. Naif HM, Cunningham AL, Alali M, et al.: A human immunodeficiency virus type 1 isolate from an infected person homozygous for CCR5delta32 exhibits dual tropism by infecting macrophages and MT2 cells via CXCR4. J Virol 2002;76:3114-3124.
31. Moore JP and Stevenson M: New targets for inhibitors of HIV-1 replication. Nat Rev Mol Cell Biol 2000;1:40-49.
32. De Clercq E: Strategies in the design of antiviral drugs. Nat Rev Drug Discov 2002;1:13-25.
33. Moore JP and Doms RW: The entry of entry inhibitors: A fusion of science and medicine. Proc Natl Acad Sci USA 2003;100: 10598-10602.
34. Clapham PR and McKnight A: Cell surfce receptors, virus entry and tropism of primate lentiviruses. J Gen Virol 2002;83: 1809-1829.
35. Zhang Y, Lou B, Lal RB, Gettie A, Marx PA, and Moore JP: Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J Virol 2000;74:6893-6910.
36. Schramm B, Penn ML, Palacios EH, Grant RM, Kirchhoff F, and Goldsmith MA: Cytopathicity of human immunodeficiency virus type 2 (HIV-2) in human lymphoid tissue is coreceptor dependent and comparable to that of HIV-1. J Virol 2000;74:9594-9600.
37. Morner A, Bjorndal A, Albert J, et al.: Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 1999;73:2343-2349.
38. Rey-Cuille MA and Hu SL: Conserved CXCR4 usage and enhanced replicative capacity of HIV-2/287, an isolate highly pathogenic in Macaca nemestrina. AIDS 2001;15:2349-2357.
39. Schuitemaker H, Kootstra NA, de Goede RE, de Wolf F, Miedema F, and Tersmette M: Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J Virol 1991;65:356-363.
40. Schuitemaker H, Koot M, Kootstra NA, et al.: Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992;66:1354-1360.
41. Richman DD and Bozzette SA: The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994;169:968-974.
42. Maas JJ, Gange SJ, Schuitemaker H, Coutinho RA, van Leeuwen R, and Margolick JB: Strong association between failure of T cell homeostasis and the syncytium-inducing phenotype among HIV-1-infected men in the Amsterdam Cohort Study. AIDS 2000;14:1155-1161.
43. Karlsson A, Parsmyr K, Sandstrom E, Fenyo EM, and Albert J: MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol 1994;32:364-370.
44. Fenyo EM, Morfeldt-Manson L, Chiodi F, et al.: Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol 1988;62:4414-4419.
45. de Roda Husman AM, Koot M, Cornelissen M, et al.: Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997;127:882-890.
46. Berger EA, Doms RW, Fenyo EM, et al.: A new classification of HIV-1. Nature 1998;391:240.
47. Singh A and Collman RG: Heterogeneous spectrum of coreceptor usage among variants within a dualtropic human immunodeficiency virus type 1 primary-isolate quasispecies. J Virol 2000; 74:10229-10235.
48. Cho MW, Lee MK, Carney MC, Berson JF, Doms RW, and Martin MA: Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. J Virol 1998;72:2509-2515.
49. Kimata JT, Kuller L, Anderson DB, Dailey P, and Overbaugh J: Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat Med 1999;5: 535-541.
50. Kwa D, Vingerhoed J, Boeser B, and Schuitemaker H: Increased in vitro cytopathicity of CC chemokine receptor 5-restricted human immunodeficiency virus type 1 primary isolates correlates with a progressive clinical course of infection. J Infect Dis 2003;187:1397-1403.
51. Kawamura T, Gulden FO, Sugaya M, et al.: R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc Natl Acad Sci USA 2003;100:8401-8406.
52. Bomsel M and David V: Mucosal gatekeepers: Selecting HIV viruses for early infection. Nat Med 2002;8:114-116.
53. Pope M and Haase AT: Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med 2003;9: 847-852.
54. Miller CJ and Shattock RJ: Target cells in vaginal HIV transmission. Microbes Infect 2003;5:59-67.
55. Veazey RS, Marx PA, and Lackner AA: Vaginal CD4+ T cells express high levels of CCR5 and are rapidly depleted in simian immunodeficiency virus infection. J Infect Dis 2003;187: 769-776.
56. Patterson BK, Landay A, Andersson J, et al.: Repertoire of chemokine receptor expression in the female genital tract: Implications for human immunodeficiency virus transmission. Am J Pathol 1998;153:481-490.
57. Lee B, Sharron M, Montaner LJ, Weissman D, and Doms RW: Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte derived macrophages. Proc Natl Acad Sci USA 1999;96: 5215-5220.
58. Granelli-Piperno A, Delgado E, Finkel V, Paxton W, and Steinman RM: Immature dendritic cells selectively replicate macrophagetropic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M-and T-tropic virus to T cells. J Virol 1998;72:2733-2737.
59. Zaitseva M, Blauvelt A, Lee S, et al.: Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: Implications for HIV primary infection. Nat Med 1997;3: 1369-1375.
60. Kawamura T, Cohen SS, Borris DL, et al.: Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. J Exp Med 2000;192:1491-1500.
61. Meng G, Sellers MT, Mosteller-Barnum M, Rogers TS, Shaw GM, and Smith PD: Lamina propria lymphocytes, not macrophages, express CCR5 and CXCR4 and are the likely target cell for human immunodeficiency virus type 1 in the intestinal mucosa. J Infect Dis 2000;182:785-791.
62. Agace WW, Amara A, Roberts AI, et al.: Constitutive expression of stromal derived factor-1 by mucosal epithelia and its role in HIV transmission and propagation. Curr Biol 2000;10:325-328.
63. Lathey JL, Tsou J, Brinker K, Hsia K, Meyer WA 3rd, and Spector SA: Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission. J Infect Dis 1999;180:344-350.
64. Fiore JR, Bjorndal A, Peipke KA, et al.: The biological phenotype of HIV-1 is usually retained during and after sexual transmission. Virology 1994;204:297-303.
65. Scarlatti G, Hodara V, Rossi P, et al.: Transmission of human immunodeficiency virus type 1 (HIV-1) from mother to child correlates with viral phenotype. Virology 1993;197:624-629.
66. Balotta C, Vigano A, Riva C, et al.: HIV type 1 phenotype correlates with the stage of infection in vertically infected children. AIDS Res Hum Retroviruses 1996;12:1247-1253.
67. Salvatori F and Scarlatti G: HIV type 1 chemokine receptor usage in mother-to-child transmission. AIDS Res Hum Retroviruses 2001;17:925-935.
68. van't Wout AB, Kootstra NA, Mulder-Kampinga GA, et al.: Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest 1994;94:2060-2067.
69. Long EM, Rainwater SM, Lavreys L, Mandaliya K, and Overbaugh J: HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res Hum Retroviruses 2002;18:567-576.
70. Casper CH, Clevestig P, Carlenor E, et al.: Link between the X4 phenotype in human immunodeficiency virus type 1-infected mothers and their children, despite the early presence of R5 in the child. J Infect Dis 2002;186:914-921.
71. Yu XF, Wang Z, Vlahov D, Markham RB, Farzadegan H, and Margolick JB: Infection with dual-tropic human immunodeficiency virus type 1 variants associated with rapid total T cell decline and disease progression in injection drug users. J Infect Dis 1998;178:388-396.
72. Spijkerman IJ, Koot M, Prins M, et al.: Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users compared with homosexual men. AIDS 1995;9: 1085-1092.
73. Lyles CM, Graham NM, Astemborski J, et al.: Cell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men. Eur J Epidemiol 1999;15:99-108.
74. Miller CJ and Hu J: T cell-tropic simian immunodeficiency virus (SIV) and simian-human immunodeficiency viruses are readily transmitted by vaginal inoculation of rhesus macaques, and Langerhans' cells of the female genital tract are infected with SIV. J Infect Dis 1999;179(Suppl. 3):S413-417.
75. Grivel JC, Penn ML, Eckstein DA, et al.: Human immunodeficiency virus type 1 coreceptor preferences determine target T-cell depletion and cellular tropism in human lymphoid tissue. J Virol 2000;74:5347-5351.
76. Bleul CC, Wu L, Hoxie JA, Springer TA, and Mackay CR: The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 1997;94:1925-1930.
77. Frank I and Pope M: The enigma of dendritic cell-immunodeficiency virus interplay. Curr Mol Med 2002;2:229-248.
78. Kawamura T, Cohen SS, Borris DL, et al.: Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. J Exp Med 2000;192:1491-1500.
79. Pohlmann S, Baribaud F, and Doms RW: DC-SIGN and DC-SIGNR: Helping hands for HIV. Trends Immunol 2001;22: 643-646.
80. Kwon DS, Gregorio G, Bitton N, Hendrickson WA, and Littman DR: DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection. Immunity 2002;16: 135-144.
81. Pope M: Mucosal dendritic cells and immunodeficiency viruses. J Infect Dis 1999;179(Suppl. 3):S427-430.
82. Geijtenbeek TB, Kwon DS, Torensma R, et al.: DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000;100:587-597.
83. Simmons G, Reeves JD, McKnight A, et al.: CXCR4 as a functional coreceptor for human immunodeficiency virus type 1 infection of primary macrophages. J Virol 1998;72:8453-8457.
84. Cornelissen M, Mulder-Kampinga G, Veenstra J, et al.: Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a nonsyncytium-inducing/SI phenotypically mixed human immunodeficiency virus population. J Virol 1995;69:1810-1818.
85. Pratt RD, Shapiro JF, McKinney N, Kwok S, and Spector SA: Virologic characterization of primary human immunodeficiency virus type 1 infection in a health care worker following needle-stick injury. J Infect Dis 1995;172:851-854.
86. Veazey RS, Marx PA, and Lackner AA: The mucosal immune system: Primary target for HIV infection and AIDS. Trends Immunol 2001;22:626-633.
87. Harouse JM, Gettie A, Tan RC, Blanchard J, and Cheng-Mayer C: Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 1999;284:816-819.
88. Smit-McBride Z, Mattapallil JJ, McChesney M, Ferrick D, and Dandekar S: Gastrointestinal T lymphocytes retain high potential for cytokine responses but have severe CD4(+) T-cell depletion at all stages of simian immunodeficiency virus infection compared to peripheral lymphocytes. J Virol 1998;72:6646-6656.
89. Veazey RS, DeMaria M, Chalifoux LV, et al.: Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998;280:427-431.
90. Veazey RS, Mansfield KG, Tham IC, et al.: Dynamics of CCR5 expression by CD4(+) T cells in lymphoid tissues during simian immunodeficiency virus infection. J Virol 2000;74:11001-11007.
91. Poles MA, Elliott J, Taing P, Anton PA, and Chen IS: A preponderance of CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection. J Virol 2001;75:8390-8399.
92. Shacklett BL, Cox CA, Sandberg JK, Stollman NH, Jacobson MA, and Nixon DF: Trafficking of human immunodeficiency virus type 1-specific CD8(+) T cells to gut-associated lymphoid tissue during chronic infection. J Virol 2003;77:5621-5631.
93. Olsson J, Poles M, Spetz AL, et al.: Human immunodeficiency virus type 1 infection is associated with significant mucosal inflammation characterized by increased expression of CCR5, CXCR4, and beta-chemokines. J Infect Dis 2000;182:1625-1635.
94. Coulomb-L'Hermine A, Emilie D, Durand-Gasselin I, Galanaud P, and Chaouat G: SDF-1 production by placental cells: A potential mechanism of inhibition of mother-to-fetus HIV transmission. AIDS Res Hum Retroviruses 2000;16:1097-1098.
95. Carrington M, Dean M, Martin MP, and O'Brien SJ: Genetics of HIV-1 infection: Chemokine receptor CCR5 polymorphism and its consequences. Hum Mol Genet 1999;8:1939-1945.
96. An P, Martin MP, Nelson GW, et al.: Influence of CCR5 promoter haplotypes on AIDS progression in African-Americans. AIDS 2000;14:2117-2122.
97. Gonzalez E, Dhanda R, Bamshad M, et al.: Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: Impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci USA 2001;98:5199-5204.
98. Kostrikis LG, Huang Y, Moore JP, et al.: A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med 1998;4:350-353.
99. Mangano A, Gonzalez E, Dhanda R, et al.: Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus. J Infect Dis 2001; 183:1574-1585.
100. Martin MP, Dean M, Smith MW, et al.: Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998;282:1907-1911.
101. Mummidi S, Ahuja SS, Gonzalez E, et al.: Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med 1998;4:786-793.
102. O'Brien TR, McDermott DH, Ioannidis JP, et al.: Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS 2000;14:821-826.
103. Cao Y, Krogstad P, Korber BT, et al.: Maternal HIV-1 viral load and vertical transmission of infection: The Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med 1997;3:549-552.
104. Sleasman JW, Aleixo LF, Morton A, Skoda-Smith S, and Goodenow MM: CD4+ memory T cells are the predominant population of HIV-1-infected lymphocytes in neonates and children. AIDS 1996;10:1477-1484.
105. Luzuriaga K and Sullivan JL: Pediatric HIV-1 infection: Advances and remaining challenges. AIDS Rev 2002;4:21-26.
106. Richardson BA, Mbori-Ngacha D, Lavreys L, et al.: Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection. J Viral 2003;77:7120-7123.
107. Mo H, Monard S, Pollack H, et al.: Expression patterns of the HIV type 1 coreceptors CCR5 and CXCR4 on CD4+ T cells and monocytes from cord and adult blood. AIDS Res Hum Retroviruses 1998;14:607-617.
108. Jameson B, Baribaud F, Pohlmann S, et al.: Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in humans and rhesus macaques. J Virol 2002;76:1866-1875.
109. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, and Weiss RA: The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984;312:763-767.
110. Klatzmann D, Champagne E, Chamaret S, et al.: T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984;312:767-768.
111. Barre-Sinoussi F, Chermann JC, Rey F, et al.: Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-871.
112. Gallo RC, Salahuddin SZ, Popovic M, et al.: Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984;224:500-503.
113. Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, and Victorino RM: CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol 2002;169:3400-3406.
114. Silvestri G, Sodora DL, Koup RA, et al.: Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 2003;18:441-452.
115. Broussard SR, Staprans SI, White R, Whitehead EM, Feinberg MB, and Allan JS: Simian immunodeficiency virus replicates to high levels in naturally infected African green monkeys without inducing immunologic or neurologic disease. J Virol 2001;75: 2262-2275.
116. Rey-Cuille MA, Berthier JL, Bomsel-Demontoy MC, et al.: Simian immunodeficiency virus replicates to high levels in sooty mangabeys without inducing disease. J Virol 1998;72:3872-3886.
117. Chakrabarti LA, Lewin SR, Zhang L, et al.: Normal T-cell turnover in sooty mangabeys harboring active simian immunodeficiency virus infection. J Virol 2000;74:1209-1223.
118. McCune JM: The dynamics of CD4+ T-cell depletion in HIV disease. Nature 2001;410:974-979.
119. Hazenberg MD, Hamann D, Schuitemaker H, and Miedema F: T cell depletion in HIV-1 infection: How CD4+ T cells go out of stock. Nat Immunol 2000;1:285-289.
120. Rowland-Jones S: HIV infection: Where have all the T cells gone? Lancet 1999;354:5-7.
121. Douek DC, Betts MR, Hill BJ, et al.: Evidence for increased T cell turnover and decreased thymic output in HIV infection. J Immunol 2001;167:6663-6668.
122. Haynes BF, Markert ML, Sempowski GD, Patel DD, and Hale LP: The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. Annu Rev Immunol 2000;18:529-560.
123. Grossman Z, Meier-Schellersheim M, Sousa AE, Victorino RM, and Paul WE: CD4+ T-cell depletion in HIV infection: Are we closer to understanding the cause? Nat Med 2002;8:319-323.
124. Kalayjian RC, Landay A, Pollard RB, et al.: Age-related immune dysfunction in health and in human immunodeficiency virus (HIV) disease: Association of age and HIV infection with naive CD8+ cell depletion, reduced expression of CD28 on CD8+ cells, and reduced thymic volumes. J Infect Dis 2003;187: 1924-1933.
125. Collaborative: Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: A collaborative re-analysis. Lancet 2000;355:1131-1137.
126. Bestilny LJ, Gill MJ, Mody CH, and Riabowol KT: Accelerated replicative senescence of the peripheral immune system induced by HIV infection. AIDS 2000;14:771-780.
127. Fagnoni FF, Vescovini R, Passeri G, et al.: Shortage of circulating naive CD8(+) T cells provides new insights on immunodeficiency in aging. Blood 2000;95:2860-2868.
128. Essajee SM, Kim M, Gonzalez C, et al.: Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children. AIDS 1999;13:2523-2532.
129. Berkowitz RD, Beckerman KP, Schall TJ, and McCune JM: CXCR4 and CCR5 expression delineates targets for HIV-1 disruption of T cell differentiation. J Immunol 1998;161:3702-3710.
130. Berkowitz RD, van't Wout AB, Kootstra NA, et al.: R5 strains of human immunodeficiency virus type 1 from rapid progressors lacking X4 strains do not possess X4-type pathogenicity in human thymus. J Virol 1999;73;7817-7822.
131. Berkowitz RD, Alexander S, and McCune JM: Causal relationships between HIV-1 coreceptor utilization, tropism, and pathogenesis in human thymus. AIDS Res Hum Retroviruses 2000;16:1039-1045.
132. Camerini D, Su HP, Gamez-Torre G, Johnson ML, Zack JA, and Chen IS: Human immunodeficiency virus type 1 pathogenesis in SCID-hu mice correlates with syncytium-inducing phenotype and viral replication. J Virol 2000;74:3196-3204.
133. Correa R and Munoz-Fernandez MA: Viral phenotype affects the thymic production of new T cells in HIV-1-infected children. AIDS 2001;15:1959-1963.
134. Blaak H, van't Wout AB, Brouwer M, Hooibrink B, Hovenkamp E, and Schuitemaker H: In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline. Proc Natl Acad Sci USA 2000;97:1269-1274.
135. Hernandez-Lopez C, Varas A, Sacedon R, et al.: Stromal cell-derived factor 1/CXCR4 signaling is critical for early human T-cell development. Blood 2002;99:546-554.
136. Muench MO, Roncarolo MG, and Namikawa R: Phenotypic and functional evidence for the expression of CD4 by hematopoietic stem cells isolated from human fetal liver. Blood 1997;89: 1364-1375.
137. Chelucci C, Casella I, Federico M, et al.: Lineage-specific expression of human immunodeficiency virus (HIV) receptor/coreceptors in differentiating hematopoietic precursors: Correlation with susceptibility to T-and M-tropic HIV and chemokine-mediated HIV resistance. Blood 1999;94:1590-1600.
138. Ruiz ME, Cicala C, Arthos J, et al.: Peripheral blood-derived CD34+ progenitor cells: CXC chemokine receptor 4 and CC chemokine receptor 5 expression and infection by HIV. J Immunol 1998;161:4169-4176.
139. Neal TF, Holland HK, Baum CM, et al.: CD34+ progenitor cells from asymptomatic patients are not a major reservoir for human immunodeficiency virus-1. Blood 1995;86:1749-1756.
140. Koka PS, Jamieson BD, Brook DG, and Zack JA: Human immunodeficiency virus type 1-induced hematopoietic inhibition is independent of productive infection of progenitor cells in vivo. J Virol 1999;73:9089-9097.
141. Stanley SK, Kessler SW, Justement JS, et al.: CD34+ bone marrow cells are infected with HIV in a subset of seropositive individuals. J Immunol 1992;149:689-697.
142. Moses A, Nelson J, and Bagby GC: The influence of human immunodeficiency virus-1 on hematopoiesis. BLood 1998;91: 1479-1495.
143. Kitchen SG and Zack JA: Distribution of the human immunodeficiency virus coreceptors CXCR4 and CCR5 in fetal lymphoid organs: Implications for pathogenesis in utero. AIDS Res Hum Retroviruses 1999;15:143-148.
144. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, and Littman DR: Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998;393:595-599.
145. Zamarchi R, Allavena P, Borsetti A, et al.: Expression and functional activity of CXCR-4 and CCR-5 chemokine receptors in human thymocytes. Clin Exp Immunol 2002;127:321-330.
146. Kitchen SG and Zack JA: CXCR4 expression during lymphopoiesis: Implications for human immunodeficiency virus type 1 infection of the thymus. J Virol 1997;71:6928-6934.
147. Zaitseva MB, Lee S, Rabin RL, et al.: CXCR4 and CCR5 on human thymocytes: Biological function and role in HIV-1 infection. J Immunol 1998;161:3103-3113.
148. Pedroza-Martins L, Gurney KB, Torbett BE, and Uittenbogaart CH: Differential tropism and replication kinetics of human immunodeficiency virus type 1 isolates in thymocytes: Coreceptor expression allows viral entry, but productive infection of distinct subsets is determined at the postentry level. J Virol 1998;72:9441-9452.
149. Majka M, Rozmyslowicz T, Ratajczak J, et al.: The limited infectability by R5 HIV of CD34(+) cells from thymus, cord, and peripheral blood and bone marrow is explained by their ability to produce beta-chemokines. Exp Hematol 2000;28:1334-1342.
150. Taylor JR Jr, Kimbrell KC, Scoggins R, Delaney M, Wu L, and Camerini D: Expression and function of chemokine receptors on human thymocytes: Implications for infection by human immunodeficiency virus type 1. J Virol 2001;75:8752-8760.
151. Huang Y, Paxton WA, Wolinsky SM, et al.: The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:1240-1243.
152. Zhou Y, Kurihara T, Ryseck RP, et al.: Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J Immunol 1998;160:4018-4025.
153. Brooks DG, Kitchen SG, Kitchen CM, Scripture-Adams DD, and Zack JA: Generation of HIV latency during thymopoiesis. Nat Med 2001;7:459-464.
154. Jamieson BD and Zack JA: In vivo pathogenesis of a human immunodeficiency virus type 1 reporter virus. J Virol 1998;72: 6520-6526.
155. Uittenbogaart CH, Anisman DJ, Jamieson BD, et al.: Differential tropism of HIV-1 isolates for distinct thymocyte subsets in vitro. AIDS 1996;10:F9-16.
156. Aldrovandi GM, Feuer G, Gao L, et al.: The SCID-hu mouse as a model for HIV-1 infection. Nature 1993;363:732-736.
157. Bonyhadi ML, Rabin L, Salimi S, et al.: HIV induces thymus depletion in vivo. Nature 1993;363:728-732.
158. Jamieson BD, Pang S, Aldrovandi GM, Zha J, and Zack JA: In vivo pathogenic properties of two clonal human immunodeficiency virus type 1 isolates. J Virol 1995;69:6259-6264.
159. Kitchen SG, Uittenbogaart CH, and Zack JA: Mechanism of human immunodeficiency virus type 1 localization in CD4-negative thymocytes: Differentiation from a CD4-positive precursor allows productive infection. J Virol 1997;71:5713-5722.
160. Rosenzweig M, Clark DP, and Gaulton GN: Selective thymocyte depletion in neonatal HIV-1 thymic infection. AIDS 1993;7: 1601-1605.
161. Kitchen SG, Killian S, Giorgi JV, and Zack JA: Functional reconstitution of thymopoiesis following HIV infection. J Virol 2000;74:2943-2948.
162. Withers-Ward ES, Amado RG, Koka PS, et al.: Transient renewal of thymopoiesis in HIV-infected human thymic implants following antiviral therapy. Nat Med 1997;3:1102-1109.
163. Kaneshima H, Su L, Bonyhadi ML, Connor RI, Ho DD, and McCune JM: Rapid-high, syncytium-inducing isolates of human immunodeficiency virus type 1 induce cytopathicity in the human thymus of the SCID-hu mouse. J Virol 1994;68:8188-8192.
164. Scoggins RM, Taylor JR Jr, Patrie J, van't Wout AB, Schuitemaker H, and Camerini D: Pathogenesis of primary R5 human immunodeficiency virus type 1 clones in SCID-hu mice. J Virol 2000;74:3205-3216.
165. Alves K, Canzian M, and Delwart EL: HIV type 1 envelope quasispecies in the thymus and lymph nodes of AIDS patients. AIDS Res Hum Retroviruses 2002;18:161-165.
166. Baskin GB, Murphey-Corb M, Martin LN, Davison-Fairburn B, Hu FS, and Kuebler D: Thymus in simian immunodeficiency virus-infected rhesus monkeys. Lab Invest 1991;65:400-407.
167. Wykrzykowska JJ, Rosenzweig M, Veazey RS, et al.: Early regeneration of thymic progenitors in rhesus macaques infected with simian immunodeficiency virus. J Exp Med 1998;187:1767-1778.
168. Lackner AA, Vogel P, Ramos RA, Kluge JD, and Marthas M: Early events in tissues during infection with pathogenic (SIVmac239) and nonpathogenic (SIVmac1A11) molecular clones of simian immunodeficiency virus. Am J Pathol 1994;145:428-439.
169. Zhang L, He T, Talal A, Wang G, Frankel SS, and Ho DD: In vivo distribution of the human immunodeficiency virus/simian immunodeficiency virus coreceptors: CXCR4, CCR3, and CCR5. J Virol 1998;72:5035-5045.
170. Stoddart C, Keir ME, and McCune JM: Personal communication. Gladstone Institute of Virology and Immunology, San Francisco, CA.
171. Schmitt N, Chene L, Boutolleau D, et al.: Positive regulation of CXCR4 expression and signaling by interleukin-7 in CD4(+) mature thymocytes correlates with their capacity to favor human immunodeficiency X4 virus replication. J Virol 2003;77:5784-5793.
172. Pedroza-Martins L, Boscardin WJ, Anisman-Posner DJ, Schols D, Bryson YJ, and Uittenbogaart CH: Impact of cytokines on replication in the thymus of primary human immunodeficiency virus type 1 isolates from infants. J VIrol 2002;76:6929-6943.
173. Gurney KB, Yang OO, Wilson SB, and Uittenbogaart CH: TCR gamma delta+ and CD161+ thymocytes express HIV-1 in the SCID-hu mouse, potentially contributing to immune dysfunction in HIV infection. J Immunol 2002;169:5338-5346.
174. Fouchier RA, Groenink M, Kootstra NA, et al.: Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992;66:3183-3187.
175. Shioda T, Levy JA, and Cheng-Mayer C: Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1992;89:9434-9438.
176. De Jong JJ, De Ronde A, Keulen W, Tersmette M, and Goudsmit J: Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: Analysis by single amino acid subtitution. J Virol 1992;66: 6777-6780.
177. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373: 117-122.
178. Coffin JM: HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 1995;267: 483-489.
179. van Rij RP, Hazenberg MD, van Benthem BHB, et al.: Early viral load and CD4+ T cell count, but not percentage of CCR5+ or CXCR4+ CD4+ T cells, are associated with R5-to-X4 HIV type 1 virus evolution. AIDS Res Hum Retroviruses 2003;19: 389-398.
180. Penn ML, Grivel JC, Schramm B, Goldsmith MA, and Margolis L: CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue. Proc Natl Acad Sci USA 1999;96:663-668.
181. Arthos J, Cicala C, Selig SM, et al.: The role of the CD4 receptor versus HIV coreceptors in envelope-mediated apoptosis in peripheral blood mononuclear cells. Virology 2002;292:98-106.
182. Kwa D, Vingerhoed J, Boeser-Nunnink B, Broersen S, and Schuitemaker H: Cytopathic effects of non-syncytium-inducing and syncytium-inducing human immunodeficiency virus type 1 variants on different CD4(+)-T-cell subsets are determined only by coreceptor expression. J Virol 2001;75:10455-10459.
183. Jekle A, Keppler OT, De Clercq E, Schols D, Weinstein M, and Goldsmith MA: In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells. J Virol 2003;77: 5846-5854.
184. Ostrowski MA, Justement SJ, Catanzaro A, et al.: Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals. J Immunol 1998;161:3195-3201.
185. Hazenberg MD, Stuart JW, Otto SA, et al.: T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: A longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 2000;95:249-255.
186. Eckstein DA, Penn ML, Korin YD, et al.: HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues. Immunity 2001;15:671-682.
187. Lee S, Lapham CK, Chen H, et al.: Coreceptor competition for association with CD4 may change the susceptibility of human cells to infection with T-tropic and macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 2000;74: 5016-5023.
188. Schutten M, van Baalen CA, Guillon C, et al.: Macrophage tropism of human immunodeficiency virus type 1 facilitates in vivo escape from cytotoxic T-lymphocyte pressure. J Virol 2001;75: 2706-2709.
189. Kwa D, Vin Rij RP, Boeser-Nunnink B, Vingerhoed J, and Schuitemaker H: Association between an interleukin-4 promoter polymorphism and the acquisition of CXCR4 using HIV-1 variants. AIDS 2003;17:981-985.
190. Llano A, Barretina J, Gutierrez A, et al.: Interleukin-7 in plasma correlates with CD4 T-cell depletion and may be associated with emergence of syncytium-inducing variants in human immunodeficiency virus type 1-positive individuals. J Virol 2001;75: 10319-10325.
191. + T cell-mediated CRC chemokine receptor 4 - simian/human immunodeficiency virus suppression in dually infected rhesus macaques. Proc Natl Acad Sci USA 2003;100:10977-10982.
192. Trkola A, Ketas T, Kewalramani VN, et al.: Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J Virol 1998;72:1876-1885.
193. Montefiori DC, Collman RG, Fouts TR, et al.: Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage. J Virol 1998;72:1886-1893.
194. Igarashi T, Brown CR, Byrum RA, et al.: Rapid and irreversible CD4+ T-cell depletion induced by the highly pathogenic simian/human immunodeficiency virus SHIV(DH12R) is systemic and synchronous. J Virol 2002;76:379-391.
195. Tokunaga K, Greenberg ML, Morse MA, Cumming RI, Lyerly HK, and Cullen BR: Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates. J Virol 2001;75:6776-6785.
196. Carrington M and O'Brien SJ: The influence of hla genotype on AIDS. Annu Rev Med 2003;54:535-551.
197. Cilliers T, Nhlapo J, Coetzer M, et al.: The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol 2003;77:4449-4456.
198. Tatt ID, Barlow KL, Nicoll A, and Clewley JP: The public health significance of HIV-1 subtypes. AIDS 2001;15(Suppl. 5):S59-71.
199. Batra M, Tien PC, Shafer RW, Contag CH, and Katzenstein DA: HIV type 1 enevlope subtype C sequences from recent seroconverters in Zimbabwe. AIDS Res Hum Retroviruses 2000;16:973-979.
200. Johnston ER, Zijenah LS, Mutetwa S, Kantor R, Kittinunvorakoon C, and Katzenstein DA: High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol 2003;77:7682-7688.
201. Alaeus A, Lidman K, Bjorkman A, Giesecke J, and Albert J: Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A-D. AIDS 1999;13:901-907.
202. Amornkul PN, Tansuphasawadikul S, Limpakarnjanarat K, et al.: Clinical disease associated with HIV-1 subtype B′ and E infection among 2104 patients in Thailand. AIDS 1999;13:1963-1969.
203. Weisman Z, Kalinkovich A, Borkow G, Stein M, Greenberg Z, and Bentwich Z: Infection by different HIV-1 subtypes (B and C) results in a similar immune activation profile despite distinct immune backgrounds. J Acquir Immune Defic Syndr 1999;21:157-163.
204. Ball SC, Abraha A, Collins KR, et al.: Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J Virol 2003;77:1021-1038.
205. Clerici M, Butto S, Lukwiya M, et al.: Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. Italian-Ugandan AIDS Project, AIDS 2000;14:2083-2092.
206. Bentwich Z, Maartens G, Torten D, Lal AA, and Lal RB: Concurrent infections and HIV pathogenesis. AIDS 2000;14:2071-2081.
207. Trouplin V, Salvatori F, Cappello F, et al.: Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotype assay. J Virol 2001;75:251-259.
208. Resch W, Hoffman N, and Swanstrom R: Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 2001;288:51-62.
209. Shankarappa R, Margolick JB, Gange SJ, et al.: Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999;73:10489-10502.
210. ten Haaft P, Murthy K, Salas M, et al.: Differences in early virus loads with different phenotypic variants of HIV-1 and SIV(cpz) in chimpanzees. AIDS 2001;15:2085-2092.
211. Michael NL and Moore JP: HIV-1 entry inhibitors: Evading the issue. Nat Med 1999;5:740-742.
212. Hendrix CW, Flexner C, MacFarland RT, et al.: Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000;44:1667-1673.
213. Strizki JM, Xu S, Wagner NE, et al.: SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:12718-12723.
214. Meanwell NA, Kadow JF: Inhibitors of the entry of HIV into host cells. Curr Opin Drug Discov Develop 2003;6:451-461.
215. Datema R, Rabin L, Hincenbergs M, et al.: Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry. Antimicrob Agents Chemother 1996;40:750-754.
216. D'Aquila RT, Sutton L, Savara A, Hughes MD, and Johnson VA: CCR5/delta(ccr5) heterozygosity: A selective pressure for the syncytium-inducing human immunodeficiency virus type 1 phenotype. NIAID AIDS Clinical Trials Group Protocol 241 Virology Team. J Infect Dis 1998;177:1549-1553.
217. de Roda Husman AM, Blaak H, Brouwer M, and Schuitemaker H: CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection. J Immunol 1999;163:4597-4603.
218. Michael NL, Chang G, Louie LG, et al.: The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997;3:338-340.
219. Aarons EJ, Beddows S, Willingham T, Wu L, and Koup RA: Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7. Virology 2001;287:382-390.
220. de Vreese K, Kofler-Mongold V, Leutgeb C, et al.: The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J Virol 1996;70:689-696.
221. Kambara K, Sato S, Tanuma J, et al.: Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134. AIDS Res Hum Retroviruses 2001;17:615-622.
222. Maeda Y, Foda M, Matsushita S, and Harada S: Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha. J Virol 2000;74:1787-1793.
223. Schols D, Este JA, Cabrera C, and De Clercq E: T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J Virol 1998;72:4032-4037.
224. Este JA, Cabrera C, Blanco J, et al.: Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. J Virol 1999;73:5577-5585.
225. Gotoh K, Yoshimori M, Kanbara K, et al.: Increase of R5 HIV-1 infection and CCR5 expression in T cells treated with high concentrations of CXCR4 antagonists and SDF-1. J Infect Chemother 2001;7:28-36.
226. Trkola A, Kuhmann SE, Strizki JM, et al.: HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA 2002;99:395-400.
227. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, and Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
228. Grossman Z and Paul WE: The impact of HIV on naive T-cell homeostasis. Nat Med 2000;6:976-977.
229. Verani A, Pesenti E, Polo S, et al.: CXCR4 is a functional coreceptor for infection of human macrophages by CXCR4-dependent primary HIV-1 isolates. J Immunol 1998;161:2084-2088.
230. Parker RA, Regan MM, and Reimann KA: Variability of viral load in plasma of rhesus monkeys inoculated with simian immunodeficiency virus or simian-human immunodeficiency virus: Implications for using nonhuman primate AIDS models to test vaccines and therapeutics. J Virol 2001;75:11234-11238.
231. Feinberg MB and Moore JP: AIDS vaccine models: Challenging challenge viruses. Nat Med 2002;8:207-210.
232. Michael NL, Brown AE, Voigt RF, et al.: Rapid disease progression without seroconversion following primary human immunodeficiency virus type 1 infection - evidence for highly susceptible human hosts. J Infect Dis 1997;175:1352-1359.
233. Montagnier L, Brenner C, Chamaret S, et al.: Human immunodeficiency virus infection and AIDS in a person with negative serology. J Infect Dis 1997;175:955-959.